ArticleInternational journal of general medicine2025
The Diagnostic Value of Serum MCP-1 Combined with OPN Detection for Early Renal Injury in Gout Patients.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in drug delivery systems for the management of gout and hyperuricemia.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the changes in serum Monocyte chemoattractant protein-1 (MCP-1) and Osteopontin (OPN) in gout patients and their diagnostic value for early renal injury. Methods: In this research, 174 gout patients (January 2022-October 2024) were divided into the early renal injury group (50 cases) and non-early renal injury group (124 cases). Additionally, 169 healthy individuals were included as controls. Clinical indicators such as serum creatinine, cystatin C (CysC), and GFR were recorded. MCP-1 and OPN levels were measured using ELISA. Pearson's correlation was used to analyze relationships; Logit regression was applied to identify influencing factors, and ROC curves assessed diagnostic value, with AUC comparisons via Z-test. Results: Serum MCP-1 and OPN levels were significantly higher in the gout group compared to controls (P<0.05) and further elevated in the early renal injury group (P<0.05). MCP-1 and OPN correlated positively with creatinine and CysC and negatively with GFR (P<0.05). Logit regression identified MCP-1 (OR: 2.765, 95% CI: 1.308-5.846) and OPN (OR: 3.019, 95% CI: 1.468-6.210) as independent risk factors (P<0.05). The AUC for diagnosing early renal injury was 0.775 (MCP-1), 0.827 (OPN), and 0.938 (combined), with the combination significantly outperforming either marker alone (Z=3.075, 2.273, P<0.05). Conclusion: The combination of serum MCP-1 and OPN in gout patients has a higher diagnostic value for early renal injury, it is obviously higher than the individual diagnosis of each indicator, and demonstrates significant clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.